<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02863705</url>
  </required_header>
  <id_info>
    <org_study_id>CMO-AP-EYE-0428</org_study_id>
    <nct_id>NCT02863705</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)</brief_title>
  <official_title>A 12-Month, Phase 4, Open Label, Multicenter, Trial to Assess the Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the long-term efficacy and safety of COMBIGAN®
      (brimonidine tartrate/timolol malate) in patients only using COMBIGAN® (brimonidine
      tartrate/timolol malate) and also in patients who require additional IOP lowering with
      LUMIGAN® (bimatoprost) 0.01%.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 5, 2016</start_date>
  <completion_date type="Anticipated">July 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean IOP change from Baseline (11AM point)</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean IOP change from Baseline (11AM point)</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Mean IOP change from baseline (11AM point) in the following patient sub-groups
patients with NTG
patients with POAG
patients taking Combigan alone
patients taking Combigan plus additional Lumigan 0.01%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean IOP change from Baseline (9AM point)</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Mean IOP change from baseline (9AM point) in the following patient sub-groups
patients with NTG
patients with POAG
patients taking Combigan alone
patients taking Combigan plus additional Lumigan 0.01%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in Mean deviation (MD) from Baseline</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in Pattern standard deviation (PSD) from Baseline</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in Visual field index (VFI) from Baseline</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in cup to disc ratio (C/D ratio) from Baseline</measure>
    <time_frame>Baseline, Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of VF progression measured as change in VF index over time</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Rate of VF progression during 12 months in the following patient sub-groups.
patients with NTG
patients with POAG
patients taking Combigan alone
patients taking Combigan plus additional Lumigan 0.01%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration of achieving the target IOP with COMBIGAN® alone</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects of achieving the target IOP with COMBIGAN® alone during 12 months</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definition of patient demographics (descriptive analysis of age and gender)</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>Define patient demographics in the following patient sub-groups:
patients with NTG
patients with POAG
patients taking Combigan alone
patients taking Combigan plus additional Lumigan 0.01%</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <condition>Normal Tension Glaucoma</condition>
  <arm_group>
    <arm_group_label>COMBIGAN®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop of COMBIGAN® in the affected eye, administered twice daily for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COMBIGAN® + LUMIGAN® 0.01%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LUMIGAN® will be administered once daily in the evening 5 minutes after COMBIGAN® instillation in patients who require additional IOP lowering.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brimonidine tartrate/timolol malate Ophthalmic Solution</intervention_name>
    <description>One drop of brimonidine tartrate/timolol malate (COMBIGAN®) Ophthalmic Solution in the affected eye, administered twice daily for 12 months</description>
    <arm_group_label>COMBIGAN®</arm_group_label>
    <arm_group_label>COMBIGAN® + LUMIGAN® 0.01%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimatoprost ophthalmic solution 0.01%</intervention_name>
    <description>Bimatoprost ophthalmic solution 0.01% (LUMIGAN®) administered once daily in the evening 5 minutes after COMBIGAN® instillation if additional lowering IOP is needed</description>
    <arm_group_label>COMBIGAN® + LUMIGAN® 0.01%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Primary open angle glaucoma (Regardless of Intraocular pressure)

          -  Previous history of topical beta-blocker use and insufficiently controlled IOP

        Exclusion Criteria:

          -  Pigmentary or exfoliative glaucoma

          -  History of angle-closure or an occludable angle by gonioscopy

          -  Prior filtration or laser iridotomy

          -  Argon laser trabeculoplasty or Selective laser trabeculoplasty performed less than 6
             months

          -  History or signs of chronic inflammatory eye disease, ocular trauma, or potentially
             progressive retinal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joy Maglambayan</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pusan National University Hospital, Pusan National University School of Medicine</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Hospital, Yeungnam University College of Medicine</name>
      <address>
        <city>Daegu</city>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital, Chungnam National University College of Medicine</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital, Chonnam National University Medical School</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital, Seoul National University College of Medicine</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>13619</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital, Seoul National University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03181</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kim's Eye Hospital, Konyang University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>07301</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2016</study_first_posted>
  <last_update_submitted>July 16, 2017</last_update_submitted>
  <last_update_submitted_qc>July 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Low Tension Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Brimonidine Tartrate, Timolol Maleate Drug Combination</mesh_term>
    <mesh_term>Bimatoprost</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

